The funding round was led by Catalio Capital Management, with participation from Iconiq and others, doubling Enveda's valuation from 12 months ago. The startup, founded in 2019, uses AI to discover new drugs from natural sources like plants and microbes. Enveda is currently testing several drugs in clinical trials, including treatments for severe skin conditions and a drug designed to help maintain weight loss after stopping GLP-1s.